This article is more than 5 years old. Information may no longer be current.
TearLab initiates international trial of TearLab Osmolarity System for diagnosing dry eye
Click Here to Manage Email Alerts
SAN DIEGO —TearLab Corporation, formerly known as OccuLogix, has initiated an international clinical trial to demonstrate the efficacy of its TearLab Osmolarity System for diagnosing and evaluating the severity of dry eye disease, the company announced in a press release.
Sponsored in part by Alcon, the TearLab Osmolarity System Core Validation Study will enroll up to 500 patients with or without a history of dry eye disease at 10 sites in the United States, Europe and Japan. Investigators will compare the system with other diagnostic tools used to establish the presence of dry eye disease. Patients will be evaluated at a single visit, and the diagnosis will be based on positive responses using established objective and subjective criteria.
TearLab expects to complete enrollment by the end of the second quarter, the release said.